Ulisse Biomed Spa
MIL:UBM

Watchlist Manager
Ulisse Biomed Spa Logo
Ulisse Biomed Spa
MIL:UBM
Watchlist
Price: 0.766 EUR -1.03% Market Closed
Market Cap: 16.9m EUR
Have any thoughts about
Ulisse Biomed Spa?
Write Note

Gross Margin
Ulisse Biomed Spa

-343.3%
Current
-811%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-343.3%
=
Gross Profit
-1.4m
/
Revenue
420.9k

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IT
Ulisse Biomed Spa
MIL:UBM
16.7m EUR
-343%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
133.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
Country IT
Market Cap 16.7m EUR
Gross Margin
-343%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.7B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

Ulisse Biomed Spa
Glance View

Market Cap
16.7m EUR
Industry
Biotechnology

Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

UBM Intrinsic Value
0.641 EUR
Overvaluation 16%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-343.3%
=
Gross Profit
-1.4m
/
Revenue
420.9k
What is the Gross Margin of Ulisse Biomed Spa?

Based on Ulisse Biomed Spa's most recent financial statements, the company has Gross Margin of -343.3%.